Combining a medicine associated with lower pulse and blood pressure with a stimulant does not establish a physiological balancing act. The useful question is whether the combination was actually tested for that outcome, in an appropriate population, for long enough to support the proposed conclusion.
What did the controlled experiment measure?
Roesch and colleagues’ 2013 open-label crossover study randomized 42 healthy adults; 40 completed it. Participants received single oral doses of guanfacine extended release 4 mg, lisdexamfetamine 50 mg, and their combination, separated by at least seven days. Plasma sampling continued through 72 hours.
The 90% confidence intervals for combination-versus-alone d-amphetamine peak concentration and total exposure were 0.967–1.019 and 0.983–1.060. Both met the study’s 0.80–1.25 criterion. Guanfacine peak concentration increased approximately 19%; its confidence interval, 1.066–1.321, exceeded that criterion, although total exposure met it.
Exposure equivalence does not establish cardiovascular cancellation
Observed supine pulse and blood-pressure changes with the combination resembled lisdexamfetamine alone, with modest increases. The authors explicitly cautioned that the experiment was not designed to assess cardiovascular effects robustly. Participants with relevant cardiac comorbidities were excluded, and the study used single doses rather than steady-state treatment.
There are two separate comparisons here. A pharmacokinetic comparison asks how coadministration changes the concentration–time profile. A cardiovascular comparison asks how the resulting drug effects interact in the person. Similar amphetamine exposure addresses the first comparison; it cannot, by itself, answer the second.
Nor does a guanfacine confidence interval outside the chosen boundary establish a dangerous interaction. The boundary supplies a prespecified statistical decision rule. Translating its failure into a clinical consequence requires evidence about the size, timing and relevance of the change. Conversely, satisfying that rule for amphetamine is not a guarantee against adverse effects.
How should this paper be used in a case review?
A report relying on this experiment should identify the proposed inference precisely: altered amphetamine exposure, an effect on blood pressure, or protection against a particular adverse event. Those claims require different evidence. A claim of cardiovascular protection would need an outcome comparison designed to test protection, rather than a concentration comparison relabeled after the fact.
For an individual record, the practical comparison remains the documented medication schedule, observations and measurements. An apparently balanced list of prescribed drugs cannot substitute for those observations. This historical healthy-volunteer experiment supplies evidence about the tested combination; it does not establish a universal rule for children, chronic treatment or patients with cardiovascular disease.
Source
Roesch B, et al. Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate. Drugs R&D. 2013;13:119–128. doi:10.1007/s40268-013-0014-8. Full text. This article interprets historical human experimental evidence.